Formulation development and pharmacological evaluation of fixed dose combination of Bombyx mori coccon shell extract, Flaxseed oil and coenzyme Q10 against doxorubicin induced cardiomyopathy in rats

Abstract

The present study aims at formulation development and pharmacological evaluation of fixed dose combination of Bombyx mori (Abresham) extract, Flaxseed oil and coenzyme Q10 (CoQ10) against doxorubicin induced myocardial toxicity in rats. Formulation (emulsion) was prepared using dry gum method (continental method), by using pestle and mortar. The formulation was characterized by performing stability studies which includes flocculation and creaming, cracking, phase inversion and accelerated studies (temperature and light). In-vivo pharmacological evaluation of Bombyx mori coccon shell extract, Flaxseed oil, CoQ10 and its fixed dose combination (FDC) were then performed. Results obtained indicates that developed FDC and extract, Oil, CoQ10 passed all stability tests and significantly prevented drug induced increase in serum levels of AST, ALT, LDH, Creatinine and lipid profile (TC, LDL, VLDL and TG) and increases the levels of HDL and antioxidant parameters—SOD, GSH and CAT (in heart tissue). It also lowered the doxorubicin induced increase in heart weight due to hypertrophy. These results were also confirmed by histopathology. The results of this study strongly indicate the cardioprotective effect of fixed dose combination of BME, Flaxseed oil and CoQ10 against doxorubicin induced myocardial toxicity.